The latest price target for Emergent BioSolutions (NYSE:EBS) was reported by Rodman & Renshaw on September 13, 2024. The analyst firm set a price target for $16.00 expecting EBS to rise to within 12 months (a possible 139.90% upside). 12 analyst firms have reported ratings in the last year.

The latest analyst rating for Emergent BioSolutions (NYSE:EBS) was provided by Rodman & Renshaw, and Emergent BioSolutions reiterated their buy rating.

The last upgrade for Emergent BioSolutions Inc happened on March 7, 2024 when Benchmark raised their price target to $5. Benchmark previously had a hold for Emergent BioSolutions Inc.

The last downgrade for Emergent BioSolutions Inc happened on August 29, 2023 when Benchmark changed their price target from N/A to N/A for Emergent BioSolutions Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Emergent BioSolutions, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Emergent BioSolutions was filed on September 13, 2024 so you should expect the next rating to be made available sometime around September 13, 2025.

While ratings are subjective and will change, the latest Emergent BioSolutions (EBS) rating was a reiterated with a price target of $16.00 to $16.00. The current price Emergent BioSolutions (EBS) is trading at is $6.67, which is out of the analyst’s predicted range.